These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25445974)

  • 1. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies.
    Abdelkader H; Pierscionek B; Alany RG
    Int J Pharm; 2014 Dec; 477(1-2):631-42. PubMed ID: 25445974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models.
    Abdelkader H; Ismail S; Hussein A; Wu Z; Al-Kassas R; Alany RG
    Int J Pharm; 2012 Aug; 432(1-2):1-10. PubMed ID: 22575752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niosomes and discomes for ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects.
    Abdelkader H; Wu Z; Al-Kassas R; Alany RG
    Int J Pharm; 2012 Aug; 433(1-2):142-8. PubMed ID: 22595640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
    J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone.
    Zagon IS; Sassani JW; McLaughlin PJ
    Cornea; 2006 Aug; 25(7):821-9. PubMed ID: 17068460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: physicochemical characterization.
    Abdelkader H; Ismail S; Kamal A; Alany RG
    Pharmazie; 2010 Nov; 65(11):811-7. PubMed ID: 21155387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.
    Zagon IS; Sassani JW; Immonen JA; McLaughlin PJ
    Clin Exp Ophthalmol; 2014 Mar; 42(2):159-68. PubMed ID: 23777539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery.
    Abdelkader H; Ismail S; Kamal A; Alany RG
    J Pharm Sci; 2011 May; 100(5):1833-46. PubMed ID: 21246556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyox and carrageenan based composite film dressing containing anti-microbial and anti-inflammatory drugs for effective wound healing.
    Boateng JS; Pawar HV; Tetteh J
    Int J Pharm; 2013 Jan; 441(1-2):181-91. PubMed ID: 23228898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
    Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D printed chitosan dressing crosslinked with genipin for potential healing of chronic wounds.
    Hafezi F; Scoutaris N; Douroumis D; Boateng J
    Int J Pharm; 2019 Apr; 560():406-415. PubMed ID: 30797865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats.
    McLaughlin PJ; Pothering CA; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2011 Oct; 236(10):1122-32. PubMed ID: 21917593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioadhesive film formed from a novel organic-inorganic hybrid gel for transdermal drug delivery system.
    Guo R; Du X; Zhang R; Deng L; Dong A; Zhang J
    Eur J Pharm Biopharm; 2011 Nov; 79(3):574-83. PubMed ID: 21723945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and in vitro characterization of novel sildenafil citrate-loaded polyvinyl alcohol-polyethylene glycol graft copolymer-based orally dissolving films.
    Xu LL; Shi LL; Cao QR; Xu WJ; Cao Y; Zhu XY; Cui JH
    Int J Pharm; 2014 Oct; 473(1-2):398-406. PubMed ID: 25079431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits.
    Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH
    Int J Pharm; 2013 Feb; 443(1-2):293-305. PubMed ID: 23333217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
    McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
    Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, optimisation and characterisation of novel wound healing film dressings loaded with streptomycin and diclofenac.
    Pawar HV; Tetteh J; Boateng JS
    Colloids Surf B Biointerfaces; 2013 Feb; 102():102-10. PubMed ID: 23006557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyvinylpyrrolidone oral films of enrofloxacin: film characterization and drug release.
    Kumar GP; Phani AR; Prasad RG; Sanganal JS; Manali N; Gupta R; Rashmi N; Prabhakara GS; Salins CP; Sandeep K; Raju DB
    Int J Pharm; 2014 Aug; 471(1-2):146-52. PubMed ID: 24858388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermosensitive Pluronic hydrogel: prolonged injectable formulation for drug abuse.
    Derakhshandeh K; Fashi M; Seifoleslami S
    Drug Des Devel Ther; 2010 Sep; 4():255-62. PubMed ID: 20957216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.